SOLICITATION NOTICE
Q -- Measure Plasma Gherlin Concentrations
- Notice Date
- 8/2/2011
- Notice Type
- Presolicitation
- NAICS
- 621511
— Medical Laboratories
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Blvd., EPS Suite 600, Rockville, Maryland, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-110128-MD
- Archive Date
- 8/31/2011
- Point of Contact
- Miguel Diaz, Phone: (301) 402-4509, Caren N Rasmussen, Phone: (301) 402-4509
- E-Mail Address
-
miguel.diaz@mail.nih.gov, cr214i@nih.gov
(miguel.diaz@mail.nih.gov, cr214i@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Contracting Office Address Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 6120 Executive Boulevard, EPS Suite 600, Room 6079, Rockville, MD 20852, UNITED STATES. Description The National Cancer Institute (NCI), Division of Cancer Epidemiology and Genetics (DCEG) plans to procure on a sole source basis with University of Southern California 1321 N. Mission Rd, LRB 207 Los Angeles, CA 90033 to measure plasma ghrelin concentrations using a radioimmunoassay. This acquisition will be processed in accordance with simplified acquisition procedures as stated in FAR Part 13.106-1(b)(1). The North American Industry Classification System Code is 621511 and the business size standard is $13.5 Million. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. The period of performance shall be twelve (12) months from date of award. Ghrelin, a hormone produced in the stomach, may be a sensitive and specific marker of gastric atrophy. DCEG, in collaboration with the University of Southern California, recently investigated serum ghrelin concentrations among male gastric and esophageal cancer cases and controls in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study cohort. Following adjustment for known risk factors including Helicobacter pylori infection and low serum pepsinogen I, those in the lowest quartile of serum ghrelin concentration at baseline had a five-fold increase in risk of gastric cancer as well as an increased risk of esophageal cancer. These results suggest that ghrelin may have an etiological role in carcinogenesis and that it may also be useful for risk stratification in early detection programs for upper gastrointestinal cancers. The purpose of this procurement is to measure plasma ghrelin concentrations in plasma from gastric cancer cases, esophageal cancer cases, and control samples from the Linxian General Population Nutrition Intervention Trial and the Shanghai Women's Health Study, in China. This procurement also provides for the measurement of serum ghrelin in additional gastric cancer cases and controls from the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study. The contractor shall determine the plasma ghrelin concentration using a radioimmunoassay. Total ghrelin will be measured by radioimmunoassay using reagents obtained from Millipore Linco Research (St. Charles, MO). This assay utilizes an antibody that is specific for total ghrelin, and is achieved by using 0.1 ml of serum in a 2-day disequilibrium assay. NCI has determined that the University of Southern California (USC) is uniquely qualified to conduct these radioimmunoassay. Using a radioimmunoassay optimized at the University of Southern California has shown the required high sensitivity, specificity, and reproducibility for ghrelin measurement. The USC laboratory has been previously used for measurement of serum/plasma ghrelin levels among gastric and esophageal cancer cases and in order for results to be comparable with previous data, the same methods and laboratory is required. This is not a solicitation for competitive quotations. However, if any interested party believes they can meet the above requirement, they may submit a statement of capabilities. All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. An original and one copy of the capability statement must be received in the NCI Office of Acquisitions on or before 11:00 AM EST on August 16, 2010. No electronic capability statements will be accepted (i.e. email or fax); an original and one copy must be sent to the NCI Office of Acquisitions to the address stated above. All questions must be in writing and can be faxed (301) 402-4513 or emailed to Miguel Diaz, Contract Specialist at miguel.diaz@mail.nih.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification in the Central Contractor Registration (CCR) www.ccr.gov and the Online Representations and Certifications Applications (ORCA), http://orca.bpn.gov. No collect calls will be accepted. Please reference solicitation number NCI-110128-MD on all correspondences.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/NCI-110128-MD/listing.html)
- Place of Performance
- Address: 1321 N. mission Road, LRB 207, Los Angeles, California, 90033, United States
- Zip Code: 90033
- Zip Code: 90033
- Record
- SN02519344-W 20110804/110802235935-50f447d5a6fc50b550a0e81e42405064 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |